Evidence map›Paper›PMID 40361115›Full record

Observational studyBMC cancer2025

Preoperative plasma cell-free DNA chromosomal instability predicts microvascular invasion in hepatocellular carcinoma: a prospective study.

Zheyue Shu, Ting Ye, Wei Wu, Menghan Su, Jingcheng Wang, Min Zhang, Ziliang Qian, Haifen Huang, Shusen Zheng, Qi Xia

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05371873 (A Prospective Study of Early Warning and Predictive Indicators Related to the Individualized Staging and Prognosis in Liver Cancer Patients), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05371873 unknown statusnot on this map

A Prospective Study of Early Warning and Predictive Indicators Related to the Individualized Staging and Prognosis in Liver Cancer Patients

TypeobservationalSponsorFirst Affiliated Hospital of Zhejiang UniversityRan2021 to 2025Enrolled250ConditionsHepatocellular CarcinomaArmsLiver resection method
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zheyue Shu *Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Ting Ye *Zhejiang University School of Medicine, Hangzhou, 310058, China.
Wei WuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Menghan SuZhejiang University School of Medicine, Hangzhou, 310058, China.
Jingcheng WangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Min ZhangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Ziliang QianThe First People's Hospital of Chenzhou, Chenzhou, 424512, China.
Haifen HuangThe First People's Hospital of Chenzhou, Chenzhou, 424512, China.
Shusen ZhengDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China. shusenzheng@zju.edu.cn.
Qi XiaZhejiang University School of Medicine, Hangzhou, 310058, China. xiaqi@zju.edu.cn.

Funding

Innovative Research Groups of National Natural Science Foundation of China 81721091Ministry of Science and Technology of the People's Republic of China, 13th Five-Year National Key Research and Development Program of China 2019YFC0840600Ministry of Science and Technology of the People's Republic of China, 13th Five-Year National Science and Technology Major Project 2018ZX10715-013-003Research Unit Project of Chinese Academy of Medical Sciences 2019-I2M-5-030Zhejiang Natural Science Foundation LQ21H030003
6 · The paper itself

Abstract

backgroundMicrovascular invasion (MVI) has been recognized as a risk factor for early recurrence after hepatectomy in patients with hepatocellular carcinoma (HCC). This study aimed to estimate the performance of an ultrasensitive chromosomal aneuploidy detector (UCAD) model for preoperative MVI prediction in operable HCC patients based on plasma cell-free DNA (cfDNA).

methodsA prospective study included HCC patients who underwent surgery in 2021. Preoperative peripheral plasma samples of eligible patients were collected to extract cfDNA, which was then subject to next generation sequencing. Low-coverage whole-genome sequencing data were analyzed for chromosomal instability using different parameters, including Z-score, chromosomal instability score (CIN score), tumor fraction (TFx) and a UCAD model (UCAD = CIN score + TFx + Z-score of all chromosomes). Receiver operating characteristic (ROC) curve was used to evaluate the performance of these parameters in preoperative MVI prediction.

resultsFinally, a total of 74 patients with HCC who undergone hepatectomy were prospectively enrolled. Chromosomal instability was evaluated by copy number alterations and oncogenes MCL1 (located at 1q), MYC (located at 8q), TERT (located at 5p), EGFR (located at 7p), and VEGFA (located at 6p) were identified in plasma cfDNA. The UCAD model was a superior parameter in predicting preoperative MVI, with an area under curve (AUC) value 0.749 with a sensitivity of 0.938 specificity of 0.466. Univariate analysis revealed that tumor size (≥ 5 cm) and UCAD (> 0.199) significantly increased the risk of MVI, which were further demonstrated by multivariate analysis, with odd ratio of 1.338 (95%CI, 1.060-1.689) and 2.028 (95%CI, 1.053-3.908) (P < 0.05).

conclusionsOur cfDNA-based UCAD model has shown a promising performance for preoperative MVI prediction in operable HCC patients.

trial registrationThis study was registered at https://clinicaltrials.gov/ on 16 May 2022, retrospectively registered, Registration number: NCT05371873.

Indexed as

Carcinoma, HepatocellularCell-Free Nucleic AcidsChromosomal InstabilityLiver NeoplasmsAdultAgedAneuploidyBiomarkers, TumorFemaleHepatectomyHumansMaleMicrovesselsMiddle AgedNeoplasm InvasivenessPreoperative PeriodBiomarkers, TumorCell-Free Nucleic AcidsCell-free DNAHepatocellular carcinomaLow-coverage whole-genome sequencingMicrovascular invasionUltrasensitive chromosomal aneuploidy detector model

Identifiers

PMID40361115
PMCPMC12076900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.